Growth-hormone (GH) peptides are marketed as a gentler, more "natural" alternative to injecting recombinant human growth hormone. The pitch is that instead of flooding the body with an external hormone, these compounds coax your own pituitary into releasing more of its own GH. That mechanism is real, but the leap from mechanism to muscle, fat loss, or anti-ageing benefit is where the marketing runs far ahead of the human data. This guide walks through how the GH axis works, what the two main peptide classes do, and what is genuinely shown in people.
The short version: these peptides can measurably raise GH and downstream IGF-1 in the short term. Whether that translates into the body-composition or recovery changes people buy them for is largely unproven at the doses and durations used recreationally.
How the GH axis actually works
GH is not released in a steady stream. The hypothalamus controls it with two opposing signals: growth-hormone-releasing hormone (GHRH), which tells the pituitary to secrete GH, and somatostatin, which tells it to stop. The result is pulsatile release — bursts of GH several times a day, largest during deep sleep — with low levels in between. GH then acts partly directly and partly by driving the liver to make insulin-like growth factor 1 (IGF-1), which mediates many of its anabolic effects.
This pulsatility matters. The body has feedback brakes: high GH and IGF-1 increase somatostatin tone, which blunts further release. Any drug that works through the pituitary is therefore working within a system designed to self-limit.
The two peptide classes
GH-releasing peptides split into two mechanistic families that are often stacked together:
- GHRH analogues, such as CJC-1295 and sermorelin. These mimic the body's own GHRH and bind the GHRH receptor on the pituitary, amplifying the natural signal to release GH. CJC-1295 without DAC is a modified GHRH fragment; the DAC (drug affinity complex) version binds albumin to extend its half-life from minutes to days.
- Growth-hormone secretagogues / ghrelin-receptor agonists (GHRPs), such as ipamorelin, GHRP-2, GHRP-6, and hexarelin. These act on the ghrelin receptor (GHS-R) and both stimulate GH release and blunt somatostatin. Ipamorelin is favoured because it is relatively selective, producing a GH pulse with little of the cortisol, prolactin, or intense hunger seen with GHRP-6.
Because the two classes act on different receptors, combining a GHRH analogue with a GHRP produces a larger, synergistic GH pulse than either alone — which is why CJC-1295 plus ipamorelin is the most common pairing.
Peptides vs injecting HGH
The key difference is pulse versus flood. Recombinant HGH (somatropin) delivers a fixed exogenous dose that raises blood GH regardless of feedback, and it suppresses your own pituitary output while you use it. GH peptides instead push your pituitary to release its own GH in something closer to a natural pulse, and because feedback brakes remain intact, they cannot drive GH as high as a large HGH dose can.
That difference cuts both ways. Peptides are less likely to produce the sustained, supraphysiological IGF-1 levels associated with HGH's side effects (fluid retention, carpal tunnel, joint pain, insulin resistance) — but for the same reason they are also less potent. Someone expecting HGH-level changes from peptides is usually disappointed. It is also worth being clear that none of the commonly used research peptides (ipamorelin, CJC-1295) are licensed medicines for body composition; sermorelin and the oral secretagogue macimorelin exist mainly as diagnostic or deficiency tools.
What the evidence actually shows
Honest summary of the human data:
- GH and IGF-1 rise. Short human studies consistently show that GHRH analogues and ghrelin-receptor agonists raise circulating GH and IGF-1 acutely. This part is well established and is the basis for using some of these agents as diagnostic tests of pituitary function.
- Body-composition outcomes are thin. There is limited controlled evidence that these peptides, at recreational doses over realistic timeframes, meaningfully increase lean mass or reduce fat in healthy adults. Most claims about muscle gain, fat loss, and recovery are extrapolated from the GH rise rather than measured directly.
- Sleep and appetite effects are plausible. Ghrelin-receptor agonists can increase deep sleep and appetite; whether this is a benefit or nuisance depends on the user's goal.
- Longer-term safety is not characterised. Sustained elevation of the GH/IGF-1 axis is theoretically relevant to insulin sensitivity and cell proliferation, and long-term human safety data for cosmetic use simply do not exist.
Practical and regulatory realities
Most of these peptides are sold as "research chemicals," not approved drugs, so purity, dose accuracy, and sterility are uncontrolled. In sport, GH-releasing peptides and GHRH analogues are prohibited at all times under the WADA Prohibited List (class S2, peptide hormones and their releasing factors), and modern assays can detect several of them. Anyone subject to testing should treat these as bannable substances, not grey-area supplements.
Bottom line
GH peptides do what they say mechanically: GHRH analogues like CJC-1295 and ghrelin-receptor agonists like ipamorelin raise your own GH and IGF-1, and stacking the two classes amplifies the pulse. What they do not have is solid human evidence that this produces the muscle, fat-loss, or anti-ageing results they are sold for, and their long-term safety at cosmetic doses is unstudied. They are a milder, self-limiting lever on the GH axis than injecting HGH — with correspondingly milder, and largely unproven, real-world effects.